The way to bring down the political temperature is to invest in the one sector where the return may be larger than the ...
Each of the several bipartisan bills being considered by Congress to promote biosimilar competition would have major ...
Rob Lott and Irene Papanicolas examine how Americans pay for health care through taxes, premiums, and out-of-pocket costs, ...
After a series of losses in constitutional challenges to the Medicare Drug Price Negotiation Program, the drug industry seems to be moving to challenging the program on statutory grounds.
Each of the several bipartisan bills being considered by Congress to promote biosimilar competition would have major implications for the pharmaceutical market.
DrPH, MPH, is an adjunct professor of health policy and management at Columbia University Mailman School of Public Health, and author of Ascending Davos: A Career Journey from the Emergency Room to ...
Value-based care is conventionally classified as an alternative payment model. That classification mistakes the output for ...
Richard W. Walker Jr., MD, MBA, IFMCP, is a physician-executive, health care entrepreneur, author, and value-based care strategist with more than three decades of experience in clinical medicine, ...
In the early parallel years, hybrid rates ran 6.2 percentage points above digital-only rates in commercial plans and 9.3 ...
From regulatory efforts to streamline approvals to emerging AI-driven decision-making, this episode explores the forces ...
Six pending federal bills would regulate private equity in health care, from an outright ban to disclosure, licensing, and antitrust tools. Rather than a categorical ban, federal policy makers could ...
Medicare has created multiple opportunities to ask about fall risk. It has not created a dependable pathway to ensure that the answer changes care.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results